Sanofi Revenue 2006-2018 | SNY

Current and historical revenue for Sanofi (SNY) from 2006 to 2018. The sum of all revenue fields included for a company's operating activities. The current revenue for Sanofi as of March 31, 2018 is .
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.973B $39.599B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $342.875B 16.39
Pfizer (PFE) United States $224.185B 13.80
Novartis AG (NVS) Switzerland $187.621B 16.09
Merck (MRK) United States $169.698B 15.17
AbbVie (ABBV) United States $149.801B 15.27
Novo Nordisk (NVO) Denmark $122.714B 20.33
GlaxoSmithKline (GSK) United Kingdom $101.582B 13.89
Eli Lilly (LLY) United States $97.721B 19.40
AstraZeneca (AZN) United Kingdom $94.553B 9.90
Bristol-Myers Squibb (BMY) United States $92.973B 18.29